1416975-49-9

Upstream product

• 1086381-36-3 4-bromo-2-tert-butoxypyridine 
• 1416975-48-8 4-[(2,6-dichloro-benzoylamino)methyl]phenylboronic acid 
• 4659-45-4 2,6-Dichlorobenzoyl chloride 

Downstream Products

• 1416975-30-8 2,6-dichloro-N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide 
• 1416975-55-7 2,6-dichloro-N-[4-(1-chloromethyl-2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide 
• 1416975-42-2 phosphoric acid mono-(4-{4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl}-2-oxo-2H-pyridin-1-ylmethyl) ester 
• 1416975-56-8 phosphoric acid di-tert-butyl ester 4-[4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl]-2-oxo-2H-pyridin-1-ylmethyl ester 

Relevant academic research and scientific papers

COMBINATION THERAPY FOR NICOTINE ADDICTION

Disclosed is a combination therapy for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of an ALDH-2 inhibitor, such as a compound of Formula (I), in combination with an amount of the nicotinic acetylcholine receptor agonist, varenicline. The disclosure further relates to methods and pharmaceutical compositions useful with the combination therapy.

ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION

Disclosed herein are methods of treating addiction to a dopamine-producing agent (e.g., amphetamine, cocaine, nicotine, opioids) in patient populations that do not exclude alcohol consumption during treatment. The methods generally comprise administering to the patient a therapeutically effective amount of an aldehyde dehydrogenase-2 (ALDH-2) inhibitor, such as compound (1).

COMBINATION THERAPY FOR PREVENTING ADDICTION

Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.

COMPOUNDS FOR THE TREATMENT OF ADDICTION

Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.